PCN72 COMPARATIVE COST ANALYSIS OF SUBCUTANEOUS TRASTUZUMAB ORIGINATOR (HERCEPTIN®) VS INTRAVENOUS TRASTUZUMAB BIOSIMILAR (KANJINTI) FROM A HOSPITAL PERSPECTIVE IN ITALY
2019
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI